Although we focused specifically on BCRs/Igs in gastric cancer, the same approach could be applied to evaluating TCRs and BCRs/Igs in other types of cancers or immune-related diseases, such as autoimmune diseases and infections, including those examined by past research [3–5, 7, 14]. This evidence concerns the gene CUBN and gastric cancer.